The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice

Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: ACR Convergence Conditions Meeting Reports Spondyloarthritis ACR Convergence 2021 AS Resource Center axial spondyloarthritis (SpA) PsA PsA Resource Center Psoriatic Arthritis Source Type: research

Related Links:

Individuals with psoriatic arthritis (a form of psoriasis characterized by chronic inflammation of joints, tendons, and ligaments) have higher rates of depression than those with non-arthritic psoriasis (a skin disease that causes red, itchy patches), according to areport in theJournal of Consultation-Liaison Psychiatry. Although there was no significant difference in suicidal thinking between psoriasis patients with and without arthritis, all psoriasis patients reported higher rates of suicidality than the general population.“We recommend routine depression screening among psoriasis patients, in particular when psor...
Source: Psychiatr News - Category: Psychiatry Tags: anhedonia anxiety APA election depression Hospital Anxiety and Depression Scale Journal of Consultation and Liaison Psychiatry psoriasis psoriatic arthritis Source Type: research
Pivotal epidemiologic studies identified modifiable cardiovascular (CV) risk factors such as dyslipidemia, smoking, diabetes, and hypertension as comorbidities associated with atherothrombosis. Many of these risk factors have emerged as therapeutic targets to prevent the development and progression of cardiovascular disease (CVD). Additional risk factors have also been recognized, including unresolved inflammation and immune dysregulation. Psoriasis and psoriatic arthritis exemplify the intersection of inflammation, immune dysregulation, and accelerated CVD. In addition to having a higher prevalence of modifiable CVD risk ...
Source: JAMA Dermatology - Category: Dermatology Source Type: research
AbstractPsoriatic arthritis (PsA) is a chronic inflammatory condition characterized by psoriasis, synovitis, enthesitis, spondylitis, and the possible association with other extra-articular manifestations and comorbidities. It is a multifaceted and systemic disorder sustained by complex pathogenesis, combining aspects of autoinflammation and autoimmunity. Features of PsA autoinflammation include the role of biomechanical stress in the onset and/or exacerbation of the disease; the evidence of involvement of the innate immune response mediators in the skin, peripheral blood and synovial tissue; an equal gender distribution; ...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
This study highlights the pharmacogenetic recommendations for dermatology therapies that have the strongest evidence at this time, highlighting those that have been incorporated in clinical practice guides. Pharmacogenetic clinical guidelines for multiple squamous cell carcinoma and psoriasis vulgaris were found in this investigation. Here, for multiple squamous cell carcinoma trichohyalin-like 1 (TCHHL1), 5-fluorouracil (5-FU) 0.5% is recommended. Along with that dapsone, Valosin-containing protein can be recommended for treating the psoriasis vulgaris. We made some clinical trials over the two diseases, and from the resu...
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: While implementation of COVID-19 vaccination programs has differed globally, these Canadian estimates are the first to reassuringly show higher COVID-19 vaccine uptake among individuals with IMIDs.PMID:35034001 | DOI:10.3899/jrheum.211148
Source: J Rheumatol - Category: Rheumatology Authors: Source Type: research
We describe prevalence and risk factors for JPsA-associated uveitis (JPsA-U).METHODS: Cross-sectional data from the National Pediatric Rheumatological Database (from 2002 to 2014) were used to characterize JPsA-U and assess risk factors for uveitis development.RESULTS: Uveitis developed in 6.6% of 1862 JPsA patients. JPsA-U patients were more frequently female (73.0 vs 62.9%, p=0.031), ANA positive (60.3 vs 37.0%, p
Source: J Rheumatol - Category: Rheumatology Authors: Source Type: research
J Rheumatol. 2022 Jan 15:jrheum.200609. doi: 10.3899/jrheum.200609. Online ahead of print.ABSTRACTOBJECTIVE: COMPLETE-PsA was an observational study of biologic-naïve Canadian adults with active psoriatic arthritis (PsA) treated with adalimumab or a non-biologic disease-modifying antirheumatic drug (nbDMARDs) regimen, after inadequate response/intolerance to a current nbDMARD treatment regimen. The aim of this analysis was to assess 12-month effectiveness of adalimumab versus nbDMARDs.METHODS: Patients enrolled between March 2012 and November 2017 were included. The following clinical parameters and patient-reported o...
Source: J Rheumatol - Category: Rheumatology Authors: Source Type: research
CONCLUSION: While implementation of COVID-19 vaccination programs has differed globally, these Canadian estimates are the first to reassuringly show higher COVID-19 vaccine uptake among individuals with IMIDs.PMID:35034001 | DOI:10.3899/jrheum.211148
Source: Journal of Rheumatology - Category: Rheumatology Authors: Source Type: research
We describe prevalence and risk factors for JPsA-associated uveitis (JPsA-U).METHODS: Cross-sectional data from the National Pediatric Rheumatological Database (from 2002 to 2014) were used to characterize JPsA-U and assess risk factors for uveitis development.RESULTS: Uveitis developed in 6.6% of 1862 JPsA patients. JPsA-U patients were more frequently female (73.0 vs 62.9%, p=0.031), ANA positive (60.3 vs 37.0%, p
Source: Journal of Rheumatology - Category: Rheumatology Authors: Source Type: research
J Rheumatol. 2022 Jan 15:jrheum.200609. doi: 10.3899/jrheum.200609. Online ahead of print.ABSTRACTOBJECTIVE: COMPLETE-PsA was an observational study of biologic-naïve Canadian adults with active psoriatic arthritis (PsA) treated with adalimumab or a non-biologic disease-modifying antirheumatic drug (nbDMARDs) regimen, after inadequate response/intolerance to a current nbDMARD treatment regimen. The aim of this analysis was to assess 12-month effectiveness of adalimumab versus nbDMARDs.METHODS: Patients enrolled between March 2012 and November 2017 were included. The following clinical parameters and patient-reported o...
Source: Journal of Rheumatology - Category: Rheumatology Authors: Source Type: research
More News: Arthritis | Psoriatic Arthritis | Rheumatology